The new JAMA newsletter contains articles on three main topics. The first is research into the leading causes of cancer death in adults under 50 years of age. The second article deals with the regulation of mifepristone by the US FDA from 2011 to 2023. The third topic concerns prenatal exposure to acid suppressants and the risk of neuropsychiatric disorders in children. A podcast is also attached to mifepristone regulation.